Catheter Precision Aktie

Catheter Precision issued 2,821 convertible Series C‑4 preferred shares for a total of $2.821 million to accredited investors. The capital is to be used for working capital, general corporate purposes and the redemption of outstanding Series B preferred shares; a later conversion of the preferred shares will dilute existing common shareholders. The placement took place despite a market capitalization of only $0.71 million and significant liquidity constraints (current ratio 0.06). Previously the company reported strong revenue growth in Q1 2026, driven in part by the electrophysiology platform and the acquisition of Flyte. » Plus sur de.investing.com

Catheter Precision’s subsidiary Flyte reports more than $1 million in revenue in the first half of 2026 and added over 1,000 new platform users; Flyte operated 118 flights with Cirrus Vision Jets. The digital booking platform uses AI-driven pricing and marketing and offers standardized route prices as well as tailored charter solutions without a membership. Despite revenue growth and a positive platform launch, parent company Catheter Precision is under financial pressure, with a sharply falling share price and high cash burn. » Plus sur de.investing.com

Flyte, a subsidiary of Catheter Precision, is expanding its fleet of Cirrus Vision Jets to offer seasonal nonstop flights between New York City and destinations such as East Hampton, Nantucket, Martha’s Vineyard, Newport and Cape Cod. The routes are expected to cut travel times of three to six hours down to 30–60 minutes and will primarily serve commuters traveling between primary and secondary residences via secondary airports. Flyte operates through Ponderosa Air under FAA Part 135; Catheter Precision, despite strong gross margins and revenue growth, faces high debt, high cash burn and a share price of $0.90 (VTAK). » Plus sur de.investing.com